As of 2025-10-17, the EV/EBITDA ratio of Jounce Therapeutics Inc (JNCE) is 1.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. JNCE's latest enterprise value is -51.62 mil USD. JNCE's TTM EBITDA according to its financial statements is -48.70 mil USD. Dividing these 2 quantities gives us the above JNCE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.2x - 12.8x | 11.0x |
| Forward P/E multiples | 15.1x - 19.9x | 18.3x |
| Fair Price | (11.11) - (8.94) | (10.69) |
| Upside | -690.9% - -575.8% | -668.8% |
| Date | EV/EBITDA |